1 atient with IBS who was briefly treated with
alosetron.
2 e blocked by the 5-HT(3) receptor antagonist
alosetron (
2 x 10(-7) M), whereas responses to 5-HT were
3 with the selective 5-HT3 receptor antagonist
alosetron (
30 microg kg-1, i.v.), did not affect the rap
4 Treatment with antidepressants and
alosetron (
a 5HT3 antagonist) has shown the most promise
5 Novel approaches include
alosetron;
a 5-HT(3) antagonist, tegaserod, a partial 5-
6 The 5-HT3 receptor (5-HT3R) antagonist
Alosetron (
Alos) reduces the symptoms of female patients
7 Alosetron also significantly decreased urgency and stool
8 324 patients were assigned 1 mg
alosetron and 323 placebo orally twice daily for 12 week
9 on occurred in 30% and 3% of patients in the
alosetron and placebo groups, respectively.
10 e development of serotonergic agents such as
alosetron and tegaserod.
11 A potent 5-HT3 antagonist, such as
alosetron,
can prevent both of these effects and is ther
12 Alosetron continues to be used under restricted availabi
13 women) with D-IBS received 1 mg twice a day
alosetron for 6 weeks; colonic transit was measured by s
14 79 (24%) of patients in the
alosetron group and 53 (16%) in the placebo group droppe
15 a greater occurrence of constipation in the
alosetron group.
16 olonic transit in response to treatment with
alosetron in D-IBS.
17 side effects have been noted with the use of
alosetron including severe constipation, fecal impaction
18 r phases of evoked afferent discharge, while
alosetron inhibited basal afferent nerve activity.
19 Alosetron is a potent and selective serotonin antagonist
20 sea associated with cancer chemotherapy, and
alosetron is employed in the treatment of IBS with diarr
21 A greater proportion of
alosetron-
treated patients than placebo-treated patients
22 Symptoms correlated temporally with
alosetron use, and symptoms abated with discontinuation
23 Alosetron was well tolerated and clinically effective in